I was invested in a company (SPPI) years ago that had an approved drug (Fusilev) that went generic. Several times the generic was put on a warning list due to limited supply and backlog. Not sure but I think Teva was one of the suppliers. Long story short the SPPI product could cover those shortages and the SP reflected that in a 50% uptick. And here we were only talking around 40 mill per quarter.